Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs), today announced that Chief Medical Officer Amir Inamdar will take part in a fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference. The conference is scheduled for June 15-16, 2026, and the fireside chat will be available on demand starting June 15 at 7:00 a.m. EDT.
Helus Pharma, the commercial operating name of Cybin Inc., is dedicated to addressing the large unmet need for individuals suffering from depression, anxiety, and other mental health conditions. The company's proprietary NSAs are synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. With class-leading data, Helus Pharma aims to improve the treatment landscape by introducing NSAs that provide durable improvements in mental health.
The company is currently developing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, Helus Pharma is advancing HLP004, another proprietary NSA in Phase 2 for generalized anxiety disorder. The company also maintains an extensive research portfolio of investigational NSAs.
For more details, the full press release is available at https://ibn.fm/KsnJW. Company updates and additional information about Helus Pharma can be found by visiting www.helus.com or following the team on X, LinkedIn, YouTube and Instagram.
The H.C. Wainwright Neuro Perspectives Conference provides a platform for key opinion leaders and industry experts to discuss advancements in neuroscience. Inamdar's participation underscores Helus Pharma's commitment to developing innovative treatments for mental health disorders and highlights the company's progress in its clinical programs.
Helus Pharma operates in Canada, the United States, the United Kingdom and Ireland. The company's focus on NSAs represents a novel approach to treating mental health conditions by targeting serotonin pathways to promote neuroplasticity, potentially offering new options for patients who have not responded adequately to existing therapies.
